PURPOSE: @entity1 with @entity135 often develop a @entity2 that can be diagnosed as @entity3 ( @entity3 ) or second @entity5 (SPT). In this study, we use @entity876 mutation analysis for validation of an allelic loss marker panel and a decision algorithm for distinguishing between @entity3 and SPT. EXPERIMENTAL DESIGN: Tumor pairs of 39 @entity1 were analyzed for @entity876 mutations, for patterns of allelic loss and immunohistochemical analysis of @entity876 expression. Results of these three analyses were compared, using mutation analysis as gold standard. RESULTS: Loss of heterozygosity (LOH) analysis indicated @entity3 in 15 and SPT in 23 cases (one inconclusive). @entity876 mutation analysis was informative in 15 cases. Based on the @entity876 mutation status alone, nine @entity5 were diagnosed as SPT and six as @entity3 . In all 15 cases the LOH analysis was in concordance with the @entity876 mutation analysis. Immunostaining for @entity876 showed promise as a first scan to diagnose @entity2 as SPT but cannot be used to diagnose @entity3 . CONCLUSION: The @entity876 mutation data validate the suitability of the LOH marker panel and decision algorithm for differential diagnosis of @entity3 and SPT in the lung. LOH analysis can theoretically be exploited in almost all cases and is less laborious than @entity876 mutation analysis.

Differential diagnosis of @entity2 following XXXX by genetic analysis.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor', 'tumors'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung tumors', 'lung tumor'] @entity876 :: ('7157', 'Gene') :: ['p53', 'TP53'] @entity3 :: ('MESH:D009362', 'Disease') :: ['DM', 'distant metastasis']
@entity135 :: (MESH:D006258,Disease) :: ['head and neck cancer']
